Nimotuzumab combined with concurrent chemoradiotherapy benefits patients with advanced nasopharyngeal carcinoma

Li, Zhanzhan; Li, Yanyan; Yan, Shipeng; Fu, Jun; Zhou, Qin; Huang, Xinqiong; Shen, Liangfang

doi:10.2147/ott.s141538

Cited by 24 publications

(13 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, Nimo concurrent with IC followed by CCRT might be the optimal mode of sequential treatment for patients with advanced NPC. The results in our study were quite different from the current thinking in the field, which could be because all the published data are based on the application of Nimo with CCRT [25][26][27]. To the best of our knowledge, there are few studies reporting that Nimo can be applied concurrently with IC to treat NPC.…”

Section: Dcontrasting

confidence: 95%

Induction chemotherapy plus nimotuzumab followed by concurrent chemoradiotherapy for advanced nasopharyngeal carcinoma

Song

Wang

et al. 2021

Arch Med Sci

View full text Add to dashboard Cite

Introduction: This study investigated the best mode for the application of nimotuzumab (Nimo) in combination with chemoradiotherapy to treat nasopharyngeal carcinoma (NPC). Material and methods: Data were prospectively collected from 168 patients with NPC from September 2009 to February 2014. One hundred twelve patients received 2-3 cycles of induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT), and 56 patients with well-matched propensity scores received IC + CCRT + Nimo. Patients were divided into 3 subgroups according to the application schedule of Nimo: group A, IC + CCRT; group B: IC (combined with Nimo) + CCRT; and group C: IC + CCRT (combined with Nimo). The 5-year overall survival (OS) and progression-free survival (PFS) and adverse events were investigated. Results: With a median follow-up of 61.4 months (range: 1.7-96.5 months), the 5-year OS and PFS for group A vs. groups B + C were 74.8 ±4.1% versus 87.0 ±4.6% (p = 0.043) and 72.7 ±4.3% vs. 83.1 ± 5.1% (p = 0.243), respectively. The 5-year OS of group B was significantly improved over that of group A (93.0 ±4.8% vs. 74.8 ±4.1%, p = 0.038); however, there was no benefit to the 5-year PFS (89.3 ±5.9% vs. 72.7 ±4.3%, p = 0.144). The 5-year OS and PFS for group C were 80.4 ±7.9% and 76.4 ±8.5%, respectively, and there was no statistically significant difference from group A (p = 0.257 and p = 0.611, respectively). No significant increase in toxicities was observed with the addition of Nimo. Conclusions: Nimo administered with chemoradiotherapy is effective for NPC. Nimo concurrent with IC followed by CCRT could be the optimal mode of sequential treatment.

show abstract

Section: Dcontrasting

confidence: 95%

Induction chemotherapy plus nimotuzumab followed by concurrent chemoradiotherapy for advanced nasopharyngeal carcinoma

Song

Wang

et al. 2021

Arch Med Sci

View full text Add to dashboard Cite

show abstract

“…In a phase II study of nimotuzumab plus RT for stage III to IVb NPC, the nimotuzumab add-on group was superior to the placebo add-on group, resulting in a significantly higher complete remission rate (90.63% vs. 51.52%, respectively, P = .02) and higher 3-year overall survival rate (84.29% vs. 77.61%, respectively, P < .05) without increasing radiation-related adverse events [37] . Our phase II study has shown that compared with chemoradiotherapy (CRT), nimotuzumab plus CRT produced the similar efficacy without increasing the acute severe dermatitis/mucositis for LA NPC [38] . Similar results were also observed in some retrospective study where nimotuzumab was combined with concurrent CRT in treatment LA NPC [27] , [28] .…”

Section: Discussionmentioning

confidence: 94%

Efficacy and Safety of Nimotuzumab Plus Radiotherapy With or Without Cisplatin-Based Chemotherapy in an Elderly Patient Subgroup (Aged 60 and Older) With Nasopharyngeal Carcinoma

Wang

Jiang

et al. 2018

Translational Oncology

View full text Add to dashboard Cite

OBJECTIVE: This study was conducted to assess the efficacy and safety of nimotuzumab combined with radiotherapy (RT) in elderly patients with nasopharyngeal carcinoma. MATERIALS AND METHODS: The clinical data of 75 nasopharyngeal carcinoma patients, who were initially treated with nimotuzumab combined with RT, were collected and retrospectively reviewed from December 2008 to April 2014. They were aged 60 to 81 years (median 64 years). The distribution of disease was stage II in 10 (13.3%), stage III in 33 (44.0%), and stage IV in 32 (42.7%). Among these patients, 59 cases received cisplatin-based chemotherapy. Survival outcomes and treatment toxicity were analyzed using IBM SPSS 19.0 software. RESULTS: With a median follow-up of 45 months (range, 13-78 months), the estimated 3-year local recurrence-free survival (LRFS), regional recurrence-free survival (RRFS), distant metastasis-free survival (DMFS), progression failure-free survival (PFS), and overall survival (OS) rates were 95.6%, 95.5%, 98.6%, 89.7%, and 89.2%, respectively. In the subgroup, 3-year OS rate in the patients with concurrent chemotherapy was 90.5% and 77.4% in patients without concurrent chemotherapy (Log-Rank = 1.795, P = .180). Univariate analysis showed that T stage and clinical stage were correlated with OS. Multivariate analysis indicated that age, T stage and tumor response at the end of treatment were independent prognosticators. Nine patients experienced grade 3 to 4 acute mucositis and 26 patients experienced grade 3-4 leukocytopenia, with no cases of skin rash and infusion reaction. Twelve patients developed mild liver function damage. No serious gastrointestinal or renal toxicities were observed. CONCLUSION: The efficacy of combined nimotuzumab with RT in elderly NPC patients was encouraging and the toxicities were accepted. In addition, nimotuzumab provides a better option for elderly patients who cannot be tolerate chemotherapy.

show abstract

“…Firstly, NPC has distinct biological characteristics from other solid tumors, so that the prognostic factors may be different; Secondly, chemoradiotherapy is the standard treatment modality for locoregionally advanced NPC currently, whereas patients in this retrospective study received combined nimotuzumab with chemoradiotherapy, so that the treatment outcomes may be changed with the addition of nimotuzumab. Several previous studies concluded that nimotuzumab combined with chemoradiotherapy benefited patients, and was more effective than chemoradiotherapy alone [10][11][12].…”

Section: Subclinical Hypercoagulation Condition Is Common In Cancer Pmentioning

confidence: 99%

“…Thus, nimotuzumab is recommended as an adjunct to radiotherapy for locoregionally advanced NPC. Subsequently, several retrospective researches confirmed that combining nimotuzumab with chemoradiotherapy increased treatment efficacy and improved prognosis with tolerable toxicities [10][11][12]. However, it is important to note that not all patients benefit from the concurrent treatment of nimotuzumab.…”

Section: Introductionmentioning

confidence: 99%

Hemastatic biomarkers as prognostic factors in locoregionally advanced nasopharyngeal carcinoma treated with nimotuzumab plus chemoradiotherapy

Sun

Chen

Xiong

et al. 2019

Preprint

View full text Add to dashboard Cite

Background: The prognostic value of hemostatic biomarkers in many tumors are well recognized. However, it remains unclear in locoregionally advanced nasopharyngeal carcinoma (NPC) patients treated with nimotuzumab plus chemoradiotherapy . In this study, we investigated pretreatment hemostatic biomarkers as prognostic factors for short-term efficacy after treatment. Methods: In total, 101 patients with stage Ⅲ or stage Ⅳa NPC were enrolled from March 2016 to December 2018. All patients received chemoradiotherapy with concurrent nimotuzumab (200 mg/week) administration. Platelet count (PLT), prothrombin time (PT), international normalized ratio (INR), thrombin time (TT), activated partial thromboplastin time (APTT), and fibrinogen (FIB) were collected before treatment. Results: There was a statistically significant association between APTT and gender ( P =0.006), while PT and INR were found to be correlated with age ( P = 0.020 and P = 0.011, respectively). Prolonged PT or elevated INR was associated with a higher CR rate after treatment ( P = 0.008 and P = 0.003, respectively). Binary logistic regression analysis demonstrated that age, T category, N category, PT and INR were independent prognostic factors for primary tumor response, whereas N category and the overall stage could independently predict cervical lymph node response. Conclusion: Pretreatment PT and INR may serve as useful prognostic biomarkers for predicting the primary tumor response to combined nimotuzumab and chemoradiotherapy in patients with locoregionally advanced NPC.

show abstract

Nimotuzumab combined with concurrent chemoradiotherapy benefits patients with advanced nasopharyngeal carcinoma

Cited by 24 publications

References 23 publications

Induction chemotherapy plus nimotuzumab followed by concurrent chemoradiotherapy for advanced nasopharyngeal carcinoma

Induction chemotherapy plus nimotuzumab followed by concurrent chemoradiotherapy for advanced nasopharyngeal carcinoma

Efficacy and Safety of Nimotuzumab Plus Radiotherapy With or Without Cisplatin-Based Chemotherapy in an Elderly Patient Subgroup (Aged 60 and Older) With Nasopharyngeal Carcinoma

Hemastatic biomarkers as prognostic factors in locoregionally advanced nasopharyngeal carcinoma treated with nimotuzumab plus chemoradiotherapy

Contact Info

Product

Resources

About